These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6119181)

  • 1. Haemodynamic effects of withdrawal of long-term treatment with beta-adrenoceptor blocking agents in subjects with essential hypertension.
    Bengtsson C; Larsson Y; Panfilov V; Sivertsson R; Aström H
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():421s-423s. PubMed ID: 6119181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacology of combined alpha-beta-blockade. II. Haemodynamic effects of labetalol.
    Lund-Johansen P
    Drugs; 1984; 28 Suppl 2():35-50. PubMed ID: 6151890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress.
    Eggertsen R
    Acta Med Scand Suppl; 1984; 689():1-46. PubMed ID: 6151343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute haemodynamic effects of carvedilol (BM 14190), a new combined beta-adrenoceptor blocker and precapillary vasodilating agent, in hypertensive patients.
    Eggertsen R; Andrén L; Sivertsson R; Hansson L
    Eur J Clin Pharmacol; 1984; 27(1):19-22. PubMed ID: 6149128
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined alpha- and beta-receptor inhibition in the treatment of hypertension.
    Prichard BN
    Drugs; 1984; 28 Suppl 2():51-68. PubMed ID: 6151891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic and physiologic considerations of adrenoceptor blockade.
    Frohlich ED; Dunn FG; Messerli FH
    Am J Med; 1983 Oct; 75(4A):9-14. PubMed ID: 6139019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Haemodynamic effects of short-term treatment with bopindolol in essential hypertension.
    Fitscha P; Meisner W; Brandstetter G; Tiso B
    Eur J Clin Pharmacol; 1988; 34(4):411-3. PubMed ID: 2900146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamic changes after acute and long-term combined alpha--beta-adrenoceptor blockade with labetalol as compared with beta-receptor blockade.
    Koch G
    J Cardiovasc Pharmacol; 1981; 3 Suppl 1():S30-41. PubMed ID: 6169958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Does chronic oral treatment with beta-receptor blockers have an effect on positive inotropic therapy of coronary patients with adrenaline after extracorporeal circulation?].
    Günnicker M; Brinkmann M; Freund U; Piotrowski J; Schieffer M; Velser U
    Herz; 1995 Dec; 20(6):399-411. PubMed ID: 8582699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of beta blockers in hypertension.
    Sleight P
    Aviat Space Environ Med; 1981 Nov; 52(11 Pt 2):S3-8. PubMed ID: 6118120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale for combined alpha-beta-adrenoceptor blockade: haemodynamic considerations.
    Koch G
    Acta Med Scand Suppl; 1982; 665():87-92. PubMed ID: 6130680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rebound phenomena following withdrawal of long-term beta-adrenoceptor blockade.
    Hjemdahl P; Olsson G
    Acta Med Scand Suppl; 1982; 665():43-7. PubMed ID: 6130674
    [No Abstract]   [Full Text] [Related]  

  • 14. Haemodynamic differences in untreated hypertension and hypertension treated with various beta-adrenoceptor antagonists.
    Weil C; Waite R
    Br J Clin Pharmacol; 1982; 13(Suppl 2):279S-283S. PubMed ID: 6125177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Labetalol: a review of its pharmacology and therapeutic use in hypertension.
    Brogden RN; Heel RC; Speight TM; Avery GS
    Drugs; 1978 Apr; 15(4):251-70. PubMed ID: 25757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade.
    Dahlöf B; Andrén L; Svensson A; Hansson L
    J Hypertens Suppl; 1983 Dec; 1(2):112-5. PubMed ID: 6152739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Haemodynamic effects of cigarette smoking during chronic selective and non-selective beta-adrenoceptor blockade in patients with hypertension.
    Houben H; Thien T; Van 'T Laar A
    Br J Clin Pharmacol; 1981 Jul; 12(1):67-72. PubMed ID: 6113840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haemodynamic effects of noise exposure before and after beta 1-selective and non-selective beta-adrenoceptor blockade in patients with essential hypertension.
    Andrén L; Hansson L; Björkman M
    Clin Sci (Lond); 1981 Dec; 61 Suppl 7():89s-91s. PubMed ID: 6274580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug information. Beta receptor blocking drugs in the treatment of hypertension. A review].
    Jensen HA; Rasmussen K
    Ugeskr Laeger; 1976 Nov; 138(47):2965-9. PubMed ID: 10660
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.